Who are Ticagrelor followed with Methoxyflurane's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ticagrelor-followed-with-methoxyflurane.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Ticagrelor followed with Methoxyflurane — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ticagrelor followed with Methoxyflurane (Ticagrelor followed with Methoxyflurane) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent combined with volatile analgesic. Area: Cardiovascular; Pain Management.

marketed Antiplatelet agent combined with volatile analgesic P2Y12 receptor (ticagrelor); NMDA receptor and other targets (methoxyflurane) Cardiovascular; Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

Ticagrelor followed with Methoxyflurane (Ticagrelor followed with Methoxyflurane) — Collegium Medicum w Bydgoszczy. Ticagrelor inhibits platelet aggregation via P2Y12 receptor antagonism, while methoxyflurane provides rapid analgesia through NMDA receptor modulation and other mechanisms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ticagrelor followed with Methoxyflurane TARGET	Ticagrelor followed with Methoxyflurane	Collegium Medicum w Bydgoszczy	marketed	Antiplatelet agent combined with volatile analgesic	P2Y12 receptor (ticagrelor); NMDA receptor and other targets (methoxyflurane)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent combined with volatile analgesic class)

Collegium Medicum w Bydgoszczy · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ticagrelor followed with Methoxyflurane — Competitive Intelligence Brief. https://druglandscape.com/ci/ticagrelor-followed-with-methoxyflurane. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab